Trial studying safety and effects for Longevity
Official title Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
ClinicalTrials.gov ID: NCT07092618
What this study is testing
What is Metformin?
Metformin is an investigational oral medicine being studied to help maintain weight loss after stopping GLP-1 medications. It is designed to lower blood sugar levels by reducing how much sugar the liver makes and improving how the body uses insulin.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares four groups to see if these medications help people keep the weight they lost when they stop GLP‑1 therapy and to check changes in blood sugar, cholesterol and quality of life over six months.
- Who it's for
- Adults who have been using GLP‑1 medications for weight loss and are planning to stop them.
- What's involved
- Participants will take the assigned medication as directed, fill out health surveys, have blood tests at the start and every 16 weeks, and share data from wearable devices with the research team.
- Time commitment
- The study lasts six months, with visits for blood tests and surveys every 16 weeks and ongoing wearable data sharing.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 85
You may be able to join if
- Existing AgelessRx patient
- Adults (40 - 85 years of age)
- Any sex
- Any ethnicity
- BMI ≥ 22 kg/m\^2
You likely can't join if
- Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or...
- History of bariatric surgery
- Use of weight-loss medications other than GLP-1s within the past 6 months
- Age \<40 years
- Contraindications to naltrexone, metformin, or rapamycin
- Significant psychiatric illness that may affect participation
See the full eligibility criteria
- Existing AgelessRx patient
- Adults (40 - 85 years of age)
- Any sex
- Any ethnicity
- BMI ≥ 22 kg/m\^2
- Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation
- Have lost at least 15 lbs during their GLP-1 use
- Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
- History of bariatric surgery
- Use of weight-loss medications other than GLP-1s within the past 6 months
- Age \<40 years
- Contraindications to naltrexone, metformin, or rapamycin
- Significant psychiatric illness that may affect participation
- Pregnant or breastfeeding individuals
The study team makes the final eligibility decision.
Where it is enrolling
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.